{"id":"cabotegravir-injectable-suspension","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions (pain, induration, erythema)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Pyrexia"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2403238","moleculeType":"Small molecule","molecularWeight":"405.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the host cell genome, thereby halting HIV replication. The long-acting injectable formulation provides sustained drug levels, enabling dosing every 2 months after an oral lead-in period.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:23.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy)"},{"name":"HIV-1 prevention in at-risk individuals (PrEP)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT05549726","phase":"PHASE4","title":"SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-01-02","conditions":"HIV","enrollment":984},{"nctId":"NCT05896748","phase":"PHASE3","title":"Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-11-08","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":94},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476},{"nctId":"NCT04371380","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-16","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05949203","phase":"","title":"Oregon PrEP at Home Study","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2023-12-01","conditions":"HIV/AIDS","enrollment":125},{"nctId":"NCT05896761","phase":"PHASE3","title":"A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-10-28","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":118},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19},{"nctId":"NCT02076178","phase":"PHASE2","title":"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":127},{"nctId":"NCT02462772","phase":"PHASE2","title":"Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa","status":"WITHDRAWN","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2015-10","conditions":"Human Immunodeficiency Virus","enrollment":""},{"nctId":"NCT01754116","phase":"PHASE1","title":"A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT01756131","phase":"PHASE1","title":"A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-09","conditions":"Infections, Human Immunodeficiency Virus and Herpesviridae","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vocabria"],"phase":"marketed","status":"active","brandName":"Cabotegravir Injectable Suspension","genericName":"Cabotegravir Injectable Suspension","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy), HIV-1 prevention in at-risk individuals (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}